Oxford Gene Technology (OGT), a UK-based molecular genetics company, has expanded its range of research-validated CytoSure Molecular Arrays to investigate DNA copy number variation (CNV) underlying a variety of genetic disorders. Designed and optimized in collaboration with experts at Emory Genetics Laboratory at Emory University School of Medicine, the arrays, which are for research use only, complement DNA sequencing by providing a tool for investigating the variety of aberrations underlying genetic disorders. The use of highly targeted, exon-focused arrays has been shown to detect CNVs as small as 12 bp in size that were missed by targeted next generation sequencing. CytoSure Molecular Arrays can be used alone or alongside sequencing.
According to OGT spokespersons, comparative genomic hybridization arrays (aCGH) are the gold standard for CNV detection, and the 60-mer oligonucleotide probes utilized by OGT’s aCGH platform have been shown to deliver superior CNV detection. The expanded CytoSure Molecular Array portfolio now enables detection of CNV in genes associated with more than 20 genetic disorders, including cardiovascular, inherited eye, intellectual disability, and neuromuscular disorders, as well as a range of inherited cancers. In addition, genes covering each disorder can be combined to create bespoke custom arrays, or further customized by the addition of novel content to suit each individual research project. To aid in extraction of meaningful results from aCGH data, all CytoSure Molecular Arrays are supplied with OGT’s CytoSure Interpret Software. Learn more about CytoSure Molecular Arrays.
